Sex-based differences in sepsis-related complications and mortality among hospitalized patients with Myelodysplastic Syndromes: A national inpatient sample analysis (2016–2022)

S Sooraj Srirangadhamu Gopu (1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States) J Jatin Thukral (Landmark Medical Center, Woonsocket, Cumberland, Rhode Island, United States) A Amanda Lussier (1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States) K Kanishka Uttam Chandani (4Mayo Clinic, Hematology-Oncology, Phoenix, United States) S Salman Ayub Jajja (NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States) D Dhruvi Joshi (Narendra Modi Medical College and Sheth L.G. Hospital, Ahmedabad, India) O Omar Alkasabrah (Landmark Medical center, Providence, Rhode Island, United States) A Ahmed Nadeem (1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States)

Abstract

Abstract Background: Patients with myelodysplastic syndromes (MDS) are highly susceptible to infections, with sepsis being a major cause of hospitalization and death. While gender differences in sepsis outcomes have been described in broader populations, their impact among patients with MDS remains poorly defined. Methods: We performed a retrospective cohort study using the National Inpatient Sample (NIS) from 2016 to 2022 to identify adult hospitalizations with co-diagnoses of MDS and sepsis. Patients were stratified by sex: male (n = 47,170) and female (n = 31,365). Multivariable logistic regression was used to evaluate the association between female sex and key outcomes: respiratory failure, encephalopathy, disseminated intravascular coagulation (DIC), Clostridioides difficile infection (CDI), fungal sepsis, and in-hospital mortality. Models were adjusted for demographics, comorbidities, and hospital characteristics. Results: Female sex was independently associated with increased odds of respiratory failure (OR 1.05, 95% CI 1.01–1.08, p = 0.011) and encephalopathy (OR 1.07, 95% CI 1.02–1.12, p = 0.010). There was a nonsignificant trend toward higher odds of CDI (OR 1.14, p = 0.086). No significant sex-based differences were observed for DIC (OR 0.84, p = 0.103), fungal sepsis (OR 0.89, p = 0.598), or in-hospital mortality (OR 0.98, p = 0.653). Conclusion: In this large national analysis of MDS patients hospitalized with sepsis, female patients were more likely to experience respiratory failure and encephalopathy, but sex was not significantly associated with mortality, DIC, or fungal infections. These findings suggest that while certain complications may differ by sex, overall in-hospital survival remains comparable between male and female patients with MDS and sepsis.Keywords: Myelodysplastic syndromes, sepsis, gender disparities, mortality, respiratory failure, encephalopathy, NIS

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 7383-7383
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (8)

S

Sooraj Srirangadhamu Gopu

1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States

J

Jatin Thukral

Landmark Medical Center, Woonsocket, Cumberland, Rhode Island, United States

A

Amanda Lussier

1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States

K

Kanishka Uttam Chandani

4Mayo Clinic, Hematology-Oncology, Phoenix, United States

S

Salman Ayub Jajja

NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States

D

Dhruvi Joshi

Narendra Modi Medical College and Sheth L.G. Hospital, Ahmedabad, India

O

Omar Alkasabrah

Landmark Medical center, Providence, Rhode Island, United States

A

Ahmed Nadeem

1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States